Description: NeuroSense Therapeutics is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include ALS, Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients. Due to the complexity of neurodegenerative diseases, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.
Home Page: www.neurosense-tx.com
NRSN Technical Analysis
Building B
Herzliya,
4672562
Israel
Phone:
972 9 799 6183
Officers
| Name | Title |
|---|---|
| Mr. Alon Ben-Noon | Co-Founder, CEO & Director |
| Mr. Or Eisenberg | Chief Financial Officer |
| Ms. Hagit Binder | VP of Operations |
| Ms. Yael Barak | Head of QA & Compliance |
| Ms. Nedira Salzman-Frenkel | Global Head of Bus. Devel. |
| Dr. Shiran Zimri Ph.D. | Head of Scientific Program |
| Dr. Ferenc Tracik M.D. | Chief Medical Officer |
| Ms. Diana Shtossel | Head of Regulatory Affairs |
| Dr. Niva Russek-Blum Ph.D. | Global Head of Discovery & IP Generator |
| Dr. Sharon Cohen Vered Ph.D. | Global Head of CMC |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.3137 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-12-09 |
| Fiscal Year End: | December |
| Full Time Employees: | 11 |